Why Buy Domino’s Pizza Stock?
When you think of growth stocks, you probably imagine technology…
Sell
49
SNPHF Quote, Financials, Valuation and Earnings
Last price:
$10.53
Seasonality move
:
3.26%
Day range:
$10.53 - $10.53
52-week range:
$9.16 - $12.64
Dividend yield:
2.18%
P/E ratio:
21.02x
P/S ratio:
1.86x
P/B ratio:
1.82x
Volume:
--
Avg. volume:
166
1-year change:
5.57%
Market cap:
$3.7B
Revenue:
$2.1B
EPS (TTM):
$0.50
Analysts' Opinion
-
Consensus RatingSanten Pharmaceutical has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Santen Pharmaceutical has an estimated downside of -- from its current price of $10.53.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $10.53.
Fair Value
-
According to the consensus of 0 analysts, Santen Pharmaceutical has -- downside to fair value with a price target of -- per share.
SNPHF vs. S&P 500
-
Over the past 5 trading days, Santen Pharmaceutical has overperformed the S&P 500 by 0.48% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Santen Pharmaceutical does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Santen Pharmaceutical revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Santen Pharmaceutical reported revenues of $479.6M.
Earnings Growth
-
Santen Pharmaceutical earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Santen Pharmaceutical reported earnings per share of $0.19.
Enterprise value:
3.1B
EV / Invested capital:
--
Price / LTM sales:
1.86x
EV / EBIT:
13.63x
EV / Revenue:
1.50x
PEG ratio (5yr expected):
--
EV / Free cash flow:
7.15x
Price / Operating cash flow:
7.84x
Enterprise value / EBITDA:
8.73x
Gross Profit (TTM):
$1.2B
Return On Assets:
6.16%
Net Income Margin (TTM):
8.78%
Return On Equity:
8.95%
Return On Invested Capital:
8.7%
Operating Margin:
17.6%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2023-06-30 | 2024-06-30 | |
| Income Statement | ||||||
| Revenue | $2.3B | $2.1B | $2B | $527.5M | $479.6M | |
| Gross Profit | $1.3B | $1.3B | $1.2B | $308.7M | $274.3M | |
| Operating Income | $300.5M | $11.3M | $260.8M | $92.9M | $84.4M | |
| EBITDA | $460.5M | $127.7M | $351.9M | $124.4M | $119.1M | |
| Diluted EPS | $0.57 | -$0.22 | $0.50 | $0.20 | $0.19 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.8B | $1.9B | $1.4B | $1.4B | $1.5B | |
| Total Assets | $4B | $3.8B | $3B | $2.9B | $2.9B | |
| Current Liabilities | $622M | $672.2M | $491.4M | $542.8M | $587.2M | |
| Total Liabilities | $987.8M | $905.9M | $811M | $806.8M | $846.1M | |
| Total Equity | $3B | $2.8B | $2.1B | $2.1B | $2B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2023-03-31 | 2024-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $410.1M | $275.1M | $503.4M | $73.1M | $100.9M | |
| Cash From Investing | -$313.3M | -$198.3M | -$42.6M | -$30.9M | -$3.8M | |
| Cash From Financing | $49.5M | -$275.6M | -$235.8M | -$77.1M | -$23.7M | |
| Free Cash Flow | $90.9M | $93M | $429.4M | $37.5M | $73M | |
SNPHF
Sector
Market Cap
$3.7B
$49.2M
Price % of 52-Week High
83.32%
48.57%
Dividend Yield
2.18%
0%
Shareholder Yield
5.61%
-0.74%
1-Year Price Total Return
5.57%
-30.94%
Beta (5-Year)
0.257
0.754
Dividend yield:
2.18%
Annualized payout:
$0.22
Payout ratio:
21.84%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$10.53
200-day SMA
Sell
Level
$10.71
Bollinger Bands (100)
Sell
Level
10.63 - 11.87
Chaikin Money Flow
Sell
Level
-45.4K
20-day SMA
Sell
Level
$10.59
Relative Strength Index (RSI14)
Sell
Level
39.68
ADX Line
Neutral
Level
Williams %R
Buy
Level
-100
50-day SMA
Sell
Level
$10.98
MACD (12, 26)
Sell
Level
-0.09
25-day Aroon Oscillator
Buy
Level
12
On Balance Volume
Neutral
Level
10.4K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.5426)
Buy
CA Score
(Annual)
Level (1.0622)
--
Beneish M-Score
(Annual)
Level (--)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-3.0982)
Buy
Piotroski F Score
(Annual)
Level (7)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.
Stock Forecast FAQ
In the current month, SNPHF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SNPHF average analyst price target in the past 3 months is --.
-
Where Will Santen Pharmaceutical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Santen Pharmaceutical share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Santen Pharmaceutical?
Analysts are divided on their view about Santen Pharmaceutical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Santen Pharmaceutical is a Sell and believe this share price will rise from its current level to --.
-
What Is Santen Pharmaceutical's Price Target?
The price target for Santen Pharmaceutical over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SNPHF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Santen Pharmaceutical is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of SNPHF?
You can purchase shares of Santen Pharmaceutical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Santen Pharmaceutical shares.
-
What Is The Santen Pharmaceutical Share Price Today?
Santen Pharmaceutical was last trading at $10.53 per share. This represents the most recent stock quote for Santen Pharmaceutical. Yesterday, Santen Pharmaceutical closed at $10.53 per share.
-
How To Buy Santen Pharmaceutical Stock Online?
In order to purchase Santen Pharmaceutical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Companies Are In The VanEck Semiconductor ETF?
There’s a lot to love about the VanEck Semiconductor ETF,…
How High Can Palantir Stock Go?
Palantir Technologies (NASDAQ:PLTR) has been one of the undisputed victors…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 121x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Sell
39
DOGZ alert for Jan 4
Dogness (International) [DOGZ] is down 20.52% over the past day.
Buy
66
DMRC alert for Jan 4
Digimarc [DMRC] is up 16.19% over the past day.
Sell
39
MSTR alert for Jan 4
MicroStrategy [MSTR] is up 13.33% over the past day.
